We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Are novel glucose‐lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta‐trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment.
- Authors
Tang, Huilin; Kimmel, Stephen E.; Hernandez, Inmaculada; Brooks, Maria M.; Cusi, Kenneth; Smith, Steven M.; Shi, Weilong; Winterstein, Almut G.; Magnani, Jared W.; Guo, Jingchuan
- Abstract
Importantly, our trial sequential analysis suggests that the sample size available provided inadequate statistical power to detect a significant treatment effect for CV outcomes in Black participants. CONCLUSIONS Although Black participants account for 11.7% of the diabetes population in the United States,8 participation of Black patients in clinical trials that evaluated novel glucose-lowering agents from 2013 to 2021 was less than 5% of trial enrollees. The composite endpoint of CV death/HHF was available in six trials (five trials for Black participants and six trials for White participants) (Figure 1). A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment.
- Subjects
SEQUENTIAL analysis; BLACK people; NEPRILYSIN; SODIUM-glucose cotransporters; MAJOR adverse cardiovascular events
- Publication
Diabetes, Obesity & Metabolism, 2022, Vol 24, Issue 1, p154
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.14540